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nprotected left main coronary artery (uLMCA) disease
as major prognostic implications and remains a therapeutic
hallenge. Current clinical practice guidelines from both
ides of the Atlantic provide a Class I recommendation
Level of Evidence: A) for coronary artery bypass grafting
CABG) in these patients. Furthermore, these guidelines
tate that percutaneous coronary interventions (PCIs) have
Class III indication for uLMCA patients otherwise eli-
ible for surgery. A recent consensus document also indi-
ates that PCI is inappropriate for uLMCA (1). Although
he evidence supporting the value of CABG in this setting
s robust, some limitations of the available information
See page 1760
hould be acknowledged. These guidelines have been
argely based upon “subgroup analyses” of 3 classical,
andomized trials comparing CABG with medical treat-
ent in stable patients back in the 1970s (2–5). Revisit-
ng these studies, we see that only the Veteran Admin-
stration Cooperative study and the European Coronary
urgery study provided data on uLMCA patients (2,3).
owever, only retrospective subgroup analyses, surpris-
ngly coming from very small cohorts of uLMCA patients
n  91 [48 vs. 43] and n  59 [28 vs. 31], respectively),
emonstrated the survival advantage of CABG. Subse-
uent post-hoc analyses revealed that the benefit concen-
rated in patients with more severe lesions and left
entricular dysfunction (2,3). The CASS randomized
tudy only included patients with moderate uLMCA
50% to 70% diameter stenosis) that could not be
nalyzed separately because they represented 1.8% of the
opulation. However, the large CASS “registry” con-
rmed the clear survival benefit after CABG (4). Finally,
he long-term durability of this benefit was confirmed in
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thec
merican College of Cardiology.
From the Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.landmark meta-analysis (5). In the following 3 decades,
ll randomized trials comparing CABG with PCI specif-
cally excluded uLMCA patients because it was consid-
red unethical to withhold surgery from them. During
hat time, extensive clinical experience and data from
ontemporary surgical studies corroborated the excellent
ong-term prognosis of CABG in uLMCA patients,
specially since the widespread utilization of arterial
rafts.
In this issue of the Journal, Mehilli et al. (6) report a
ighly provocative trial in which uLMCA patients were
ystematically offered PCI with drug-eluting stents (DES).
sing an elegant noninferiority study design, uLMCA
atients were randomized to sirolimus-eluting stents (SES)
r paclitaxel-eluting stents (PES). Results were excellent
nd comparable in both arms. However, are stents ready for
rime time in uLMCA (7)?
rom the initial steps to large observational studies. The
romising results of balloon angioplasty in this location
oon became overshadowed by high restenosis rates, and the
nterest for this approach rapidly waned. In the bare-metal
tent era, most studies included many emergency cases or
atients deemed inoperable, explaining the unsatisfactory
esults in early series. However, since the advent of DES,
LMCA patients are being increasingly considered for PCI.
nitial reports warned of the potential risk of sudden death
ssociated with uLMCA restenosis, but currently, the em-
hasis has shifted to the identification of patients at risk for
hrombosis. In the study of Chieffo et al. (8) with 731
LMCA patients, however, the incidence of DES throm-
osis at 2.5 years was only 0.9%. Recent observational
tudies have demonstrated similar rates of death and major
dverse events in patients undergoing DES implantation
nd CABG (9,10) although the need for revascularization
as been consistently lower after surgery. Again, a substan-
ial number of patients treated with DES were poor surgical
andidates. Propensity score matching is considered a more
ffective means of accounting for imbalances in baseline
haracteristics than conventional stratification or multivar-
ate covariate adjustments. Studies using this methodology
ave confirmed equivalent results with both revasculariza-
ion strategies (9,10). Furthermore, a systematic review of
LMCA stenting (11) (1,278 patients, median follow-up 10
onths) demonstrated a mortality rate of 5.5% and a target
essel revascularization rate of 6.5% after DES. Interest-
ngly, rates of adverse events were reduced with DES as
ompared with bare-metal stents or CABG.
Long-term data are also rapidly accumulating. Recently,
large multicenter study demonstrated a 3-year mortality
ate of 6.2% after elective DES for uLMCA (12). The
AIN-COMPARE registry (13) analyzed an impressive
umber of uLMCA patients treated at 12 institutions in
orea (1,102 stenting and 1,138 CABG). Comparable
ubgroups were identified by propensity score matching. In
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Left Main Coronary Artery Stenting May 12, 2009:1769–72ntial strategy,” and 97% of patients were eligible for
urgery. One-half of them had bifurcation involvement and
oncomitant multivessel disease. At 3 years, the primary end
oint (death, myocardial infarction, and stroke) was similar
n both groups.
vidence stemming from randomized studies. Erglis
t al. (14) randomized 103 uLMCA patients to either
are-metal stents or PES. Lesions were pre-dilated with
utting balloons, and results were optimized with intravas-
ular ultrasound. No hospital mortality was found, and the
estenosis rate was significantly reduced in the PES arm
22% vs. 5.7%). To date, however, only a single randomized
tudy has directly compared stenting with CABG in
LMCA patients. The LEMANS trial (15) allocated 52
atients to stenting and 53 to CABG. At 30 days, major
vents were significantly reduced after stenting and a similar
rend was maintained at 12 months. The primary end point
improvement in left ventricular ejection fraction) favored
oronary stenting. Despite the reduced sample size, these
esults are relevant considering that most patients had distal
LMCA and multivessel disease and that DES were only
sed in 35% of cases.
Recently, data from the SYNTAX randomized study
PCI with PES vs. CABG in patients with uLMCA/
-vessel disease), have been reported (16). Primary end
oint (equivalence in the composite of death, stroke, myo-
ardial infarction, and repeat revascularization at 1 year) was
ot met, although rates of death and myocardial infarction
ere similar in the 2 arms. A new “score,” designed to assess
oronary anatomy complexity, suggested comparable results
ith both strategies in patients with “simple” anatomy.
urthermore, in the large (stratified by protocol) patient
ohort of uLMCA patients (705 patients: 357 PES, 348
ABG) the primary end point was similar in both arms
lthough, again, repeat revascularization rate was higher and
troke rates were lower after PES. The authors nicely
ighlighted the limitations of these subgroup analyses (16).
o be fair, however, we should emphasize here how closely
hese analyses mirror (now with a larger number of patients)
hose previously performed in the pivotal trials establishing
he superiority of CABG over medical therapy in this
etting. Subgroup analyses should be just considered as
hypothesis generating,” but all available information—even
hat coming from historical surgical studies—should be
ritically analyzed with the same standards. Only then will
e be able to identify areas for improvement in patient care
nd the potential benefit of emerging technologies. The
imited duration of follow-up in the SYNTAX study (1
ear) remains a matter of concern as the benefit of surgery
ight accrue with time. Despite these caveats, results of the
YNTAX study will greatly impact uLMCA revasculariza-
ion decisions in the near future. Lastly, the results of the
OMBAT and REVASCULARIZE trials, directly com-
aring DES with CABG in uLMCA, are eagerly awaited.
At this point, some major questions arise: Should currentuidelines be updated to incorporate all of these relevant oew pieces of evidence? Is current evidence-based informa-
ion robust enough to forget about CABG and directly
valuate the best PCI strategy in uLMCA? Equipoise,
efined as sufficient uncertainty regarding the potential
enefits of “competing” therapeutic strategies, is required
efore a randomized trial is performed (7). We believe that
urrently, not only CABG versus DES trials are justi-
ed—and indeed needed—but also trials comparing head-
o-head different coronary interventions in this critical
natomic scenario.
resent study. The ISAR-LEFT-MAIN randomized trial
6) sheds additional light on this controversial subject and
rovides compelling evidence supporting the value of DES
n uLMCA patients. Some issues deserve consideration.
irst of all—and surprisingly for a randomized study—most
LMCA patients were eventually randomized, ensuring the
xternal validity of the study to illuminate everyday clinical
ractice. Second, this study constitutes the largest dedicated
andomized trial ever performed in uLMCA (607 patients).
herefore, the clinical evidence generated, both in terms of
afety and efficacy, is sound and undisputable. Overall,
0-day mortality was only 1.3%, a striking figure consider-
ng that one-third of patients had a EuroSCORE 6. The
ombined primary end point (death, myocardial infarction,
arget vessel revascularization) was similar in both groups
13.6% PES vs. 15.8% SES). Third, most patients had a
omplex coronary anatomy, with two-thirds having mul-
ivessel disease. Surprisingly, only 12% of eligible patients
nderwent CABG. Nevertheless, interventions in lesions
ifferent from the uLMCA were only performed in 21% of
ases, suggesting that incomplete revascularization was fre-
uently obtained. Whether this problem would ultimately
mpair symptomatic status or long-term prognosis, should
e investigated in an extended clinical follow-up. Further-
ore, two-thirds of patients had involvement of the distal
ifurcation (mostly treated with “culotte” stenting and final
kissing balloon”). This is important because restenosis was
irtually always confined to this location, confirming previ-
us observational studies with different stenting strategies
11). In this regard, data of patients with ostial/midshaft
esions would have been of interest. Fourth, additional
ngiographic data (late loss, loss index) would have com-
lemented the equivalent restenosis rates (secondary end
oint) and might have unraveled potential mechanistic
ifferences among DES in this setting. Last, but not least,
he authors should be commended for providing the longest
linical follow-up available (2 years) together with the
-year primary end point. No episodes of late or very late
tent thrombosis occurred, and only 1% of patients required
ABG for restenosis. This information is highly reassuring.
nsettled issues. This unique site of the coronary tree,
nitially targeted with success by Andreas Grüentzig in his
ioneering experience, is readily accessible. However, the
nterventional cardiology community should be proud of
aving adopted a largely cautious approach in the treatment
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May 12, 2009:1769–72 Left Main Coronary Artery Stentingimple procedure (yes, we can), the burning question is:
hould we just do it?
“Emergency” stenting is widely used in uLMCA patients
resenting with acute myocardial infarction or cardiogenic
hock. Until now, “elective” uLMCA stenting has been
estricted to patients at high surgical risk. In recent years,
owever, elective stenting is being offered to good surgical
andidates. Stenting is less invasive, reduces hospitalization
ength and postoperative disabilities, and allows subsequent
ABG if necessary. Elective stenting appears particularly
ttractive in octogenarians (17) and in patients with a high
uroSCORE, although results are also compromised in
hese patients (17). In Europe, up to one-third of all
LMCA patients are treated with stents, accounting for 3%
f all PCI procedures (7,13,18). Therefore, some recom-
endations to address this emerging scenario should be
ssued. A clinical and angiographic scoring system should be
evised and subsequently validated to assist decision mak-
ng. Although speculative, the variables in Table 1 are
roposed to help in this regard. In many centers, patients
ith “simple” ostial/midshaft lesions are considered for
lective stenting. After a balanced counseling that empha-
izes the current lack of very long-term data after DES,
any patients accept the trade-off of repeat revasculariza-
ion for a lesser invasivity. In complex lesions, this enthu-
iasm should be tempered to avoid jeopardizing patient
afety. Alternatively, “routine” PCI in uLMCA—challenging
he standard of care—should be further restricted and only
erformed under the umbrella of controlled studies.
Many technical issues remain unsettled. An ideal me-
hanical solution to address uLMCA bifurcations remains
lusive (8–11). Furthermore, stent underexpansion and
alapposition appear particularly germane to uLMCA
atients. These problems, readily detected with intravascu-
ar ultrasound, should be aggressively managed. Heavy
alcification may be tackled with rotational atherectomy to
elevant Variables for “Elective”LMCA Stenting in Patients Eligible for CABG








LAD and LCX ostial disease
LCX size
Calcium





Vessels suitable for coronary artery bypass grafting (CABG).
LAD  left anterior descending coronary artery; LCX  left circumflex coronary artery; RCA 
ight coronary artery; uLMCA  unprotected left main coronary artery.uarantee full stent expansion. In patients with poor ven-
ricular function and anticipated procedural complexity,
rophylactic cardiopulmonary support might be indicated.
evertheless, the value of all these “adjuvant” strategies
emains largely speculative. Indeed, in the ISAR-LEFT-
AIN trial, despite a complex patient mix, rotational
therectomy and intra-aortic balloon pumping were only
sed in 1% of cases, whereas intravascular ultrasound was
ot used. In this regard, the meticulous care paid by the
nvestigators to ensure an optimal antiplatelet effect might
e implicated in their favorable results (6). Some final issues
eserve consideration. Should surveillance late angiography
e routinely scheduled? Should “indefinite” dual antiplatelet
herapy be recommended? Should point-of-care assessment
f platelet function be performed? Most of these questions
emain undefined yet they are proposed as safety nets for
atients with lesions treated at this critical site.
inal remarks. The study of Mehilli et al. (6) demonstrat-
ng the efficacy of DES in uLMCA patients is provocative
nd definitively, constitutes a major advancement in knowl-
dge. Undoubtedly, this novel information, together with
ata emerging from other recent studies, will reshape the
andscape of interventional cardiology. From now on,
LMCA should be perceived by surgeons and intervention-
lists as a challenging setting where only a judicious com-
ined clinical assessment will allow the selection of the most
ppropriate revascularization strategy for each individual
atient. Our personal bias, however, is that interventional
ardiology will eventually conquer uLMCA. In “favorable”
esions, this is already happening. In complex cases, this
aradigm shift will be more gradual, but considering the
uperb results of the ISAR-LEFT-MAIN trial, it appears
nevitable. New generation DES, together with refined
echniques and improved antiplatelet regimens, will allow
ore effective tackling of this critical anatomic scenario with
better safety profile. Although additional information,
specially regarding very late outcome, is eagerly needed, the
ccumulating evidence already suggests that the use of DES
or uLMCA patients is no longer at the crossroads, but
ather is rapidly eroding the last bastion of CABG and
uccessfully “Crossing the Rubicon.”
eprint requests and correspondence: Dr. Fernando Alfonso,
ardiovascular Institute, San Carlos University Hospital, Plaza de
risto Rey, Madrid 28040, Spain. E-mail: falf@hotmail.com.
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